SHR-4610 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 1/2. The sponsor with the most trials is Suzhou Suncadia Biopharmaceuticals Co., Ltd (1). The most-studied condition is Advanced Renal Cell Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
NCT07231211 · ClinicalTrials.gov ↗ · Solid Tumors
|
Phase 1/2 | Recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | China |
|
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
NCT07239596 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma
|
Phase 1/2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1 |
| Shanghai Shengdi Pharmaceutical Co., Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name SHR-4610 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Suzhou Suncadia Biopharmaceuticals Co., Ltd (1) and Shanghai Shengdi Pharmaceutical Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SHR-4610 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-4610 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-4610 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.